Cetirizine Safety in G6PD Deficiency
Cetirizine can be safely given to children with G6PD deficiency, as there is no evidence linking this second-generation antihistamine to hemolytic anemia or other G6PD-related complications.
Evidence-Based Safety Profile
After comprehensive literature review, cetirizine is not among the medications contraindicated in G6PD deficiency. 1 A systematic evidence-based review identified only seven medications with solid evidence for prohibition in G6PD-deficient patients: dapsone, methylthioninium chloride (methylene blue), nitrofurantoin, phenazopyridine, primaquine, rasburicase, and tolonium chloride. 1 Cetirizine is notably absent from this list.
Mechanism of Safety
The medications that cause hemolysis in G6PD deficiency are potent oxidants that overwhelm the reduced NADPH production capacity in affected red blood cells. 2 For example:
- Primaquine is absolutely contraindicated due to its ability to induce hemolytic anemia in G6PD-deficient patients 2
- Dapsone should be avoided as it causes methemoglobinemia and red blood cell hemolysis by overcoming the reductive capacity of G6PD 3
- Rasburicase is contraindicated in patients with known G6PD deficiency 4
Cetirizine, as a second-generation antihistamine, does not possess oxidant properties that would trigger hemolysis in G6PD-deficient individuals. 1
Age-Appropriate Dosing Considerations
While cetirizine is safe regarding G6PD status, age-appropriate prescribing remains important:
- For infants 6-11 months: Cetirizine can be administered at 0.25 mg/kg twice daily, with documented safety in randomized controlled trials 5, 6
- For children 2-5 years: FDA-approved dosing is 2.5 mg once or twice daily 5
- For infants under 6 months: Cetirizine is not recommended due to lack of safety data in this age group, not due to G6PD concerns 5, 7
Clinical Pitfalls to Avoid
Do not confuse cetirizine with medications that are genuinely contraindicated in G6PD deficiency. 1 Many compounds have been wrongly cited as causing hemolysis because they were administered during infection-related hemolytic episodes, leading to inappropriate medication restrictions. 1
Screening for G6PD deficiency is only necessary before starting known oxidant drugs (primaquine, dapsone, rasburicase, etc.) in patients of Mediterranean, African, Indian, or Southeast Asian descent. 3 This screening is not required before prescribing cetirizine.
Renal Function Considerations
The only modification needed for cetirizine relates to renal function, not G6PD status:
- Moderate renal impairment: Dose reduction required 5, 7
- Severe renal impairment: Cetirizine should be avoided 5, 7
In summary, G6PD deficiency does not contraindicate cetirizine use at any age where the medication is otherwise appropriate. 1